Molecular perspectives on the non-responder phenomenon

Drug Discovery Today

Volumn 14, Issue 7-8, 2009, Pages 373-379

  Jackson, David B ^a  

^a LIFE Biosystems GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CETUXIMAB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; INNO 404; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NILOTINIB; PANITUMUMAB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANEMIA; BARRETT ESOPHAGUS; BILE DUCT CARCINOMA; BREAST CANCER; CANCER PATIENT; CANCER RELAPSE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MOLECULAR MECHANICS; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 62849123231     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.01.005     Document Type: Review

References (67)

1. Soverini S., et al. Imatinib mesylate for the treatment of chronic myeloid leukemia. Exp. Rev. Anticancer Ther. 8 (2008) 853-864
2. Alvarez R.H., et al. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin. Hematol. 44 Suppl. 1 (2007) S4-S14
3. Jørgensen H.G., et al. Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 99 (2002) 713-715
4. Hamada A., et al. Interaction of imatinib mesilate with human P-glycoprotein. J. Pharmacol. Exp. Ther. 307 (2003) 824-828
5. Peng B., et al. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 44 (2005) 879-894
6. Heinrich M.C., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
7. Picard S., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109 (2007) 3496-3499
8. Blasdel C., et al. Therapeutic drug monitoring in CML patients on imatinib. Blood 110 (2007) 1699-1701
9. Gorre M.E., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
10. Schindler T., et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289 (2002) 1938-1942
11. Manley P.W., et al. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer 38 (2002) S19-S27
12. Nagar B., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243
13. Hofmann W.K., et al. Ph (+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99 (2002) 1860-1862
14. Hochhaus A., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
15. Roche-Lestienne C., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
16. Branford S., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99 (2002) 3472-3475
17. Al-Ali H.K., et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol. J. 5 (2002) 55-60
18. Shah N.P., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
19. Rourmiantsev S., et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the ABL kinase domain P-loop. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10700-10705
20. Roche-Lestienne C., et al. Several types of mutations of the ABL gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
21. Sattler M., et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 275 (2000) 24273-24278
22. Koptyra M., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108 (2006) 319-327
23. Dutta P.R., and Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 254 (2007) 165-177
24. Fong T., et al. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J. Thorac. Oncol. 3 (2008) 303-310
25. Taron M., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11 (2005) 5878-5885
26. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
27. Cappuzzo F., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97 (2005) 643-655
28. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
29. Shih J.Y., et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced non-small cell lung cancer. Int. J. Cancer 118 (2006) 963-969
30. Paz-Ares L., et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). ASCO annual Meeting (2006)
31. Inoue A., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24 (2006) 3340-3346
32. Asahina H., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 95 (2006) 998-1004
33. Pao W., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2 (2005) e73
34. Gonçalves A., et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer (2008) 169
35. Lièvre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66 (2006) 3992-3995
36. Di Nicolantonio F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26 (2008) 5705-5712
37. Sordella R., et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
38. Soria J.C., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8 (2002) 1178-1184
39. Cappuzzo F., et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 17 (2006) 1120-1127
40. Bean J., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20932-20937
41. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
42. Erjala K., et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 12 (2006) 4103-4111
43. Cunha R.A., et al. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr. Pharm. Des. 14 (2008) 1512-1524
44. Butanda-Ochoa A., et al. Recognition and activation of ryanodine receptors by purines. Curr. Med. Chem. 13 (2006) 647-657
45. Yoshimura H. The potential of caffeine for functional modification from cortical synapses to neuron networks in the brain. Curr. Neuropharmacol. 3 (2005) 309-316
46. Ravi D., et al. Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism. Mol. Cell Biochem. 308 (2008) 193-200
47. Bantscheff M., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25 (2007) 1035-1044
48. Karaman M.W., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008) 127-132
49. Clark G.M., et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin. Lung Cancer 7 (2006) 389-394
50. Chang A., et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J. Thorac. Oncol. 1 (2006) 847-855
51. Arteaga C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 7 (2002) 31-39
52. Miettinen P.J., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376 (1995) 337-341
53. Luetteke N.C., et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 8 (1994) 399-413
54. Harari P.M., and Huang S.M. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 976-983
55. Nagy P., et al. Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp. Cell Res. 285 (2003) 39-49
56. Weihua Z., et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 13 (2008) 385-393
57. FDA's Critical Path Initiative website. http://www.fda.gov/oc/initiatives/criticalpath/
58. Lee J.W., et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int. J. Cancer 113 (2005) 510-511
59. Generali D., et al. EGFR mutations in exons 18-21 in sporadic breast cancer. Ann. Oncol. 18 (2007) 203-205
60. Bhargava R., et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. 18 (2005) 1027-1033
61. Barber T.D. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351 (2004) 2883
62. Schilder R.J., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11 (2005) 5539-5548
63. Sihto H., et al. Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. J. Mol. Med. 83 (2005) 976-983
64. Kwak E.L., et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 12 Pt 1 (2006) 4283-4287
65. Gwak G.Y., et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J. Cancer Res. Clin. Oncol. 131 (2005) 649-652
66. Na I.I., et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur. J. Cancer 43 (2007) 520-526
67. Loeffler-Ragg J., et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur. J. Cancer 42 (2006) 109-111